#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Christof Westenfelder Email
Founder & CEO . SymbioCellTech
How to contact Christof Westenfelder
Join and see Christof's contact info for free!Current Roles
Employees:
5Revenue:
$775kAbout
SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.SymbioCellTech Address
615 Arapeen Drive Suite 210Salt Lake City, UT
United States